Efficacy of azatyrosine-phenylbutyric hydroxamides, a histone deacetylase inhibitor, on chemotherapy-induced gastrointestinal mucositis

Po Lin Liao, Shih Hsuan Huang, Chien Hung Hung, Wei Kuang Huang, Chi Hao Tsai, Jaw Jou Kang, Hui Po Wang, Yu Wen Cheng

研究成果: 雜誌貢獻文章

摘要

Gastrointestinal mucositis is a serious side effect of chemotherapy. Currently, no effective treatment exists for chemotherapy-induced mucositis, prompting the need to develop an anti-mucositis agent for use in clinics. The present study investigated whether azatyrosine-PBHA (AzP), a histone deacetylase inhibitor, has a therapeutic effect on intestinal mucosa. The results indicated that AzP did not affect the proliferation and viability of cancer cells, outcomes that are achieved by suberoylanilide hydroxamic acid (SAHA). However, AzP could decrease production of the inflammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor-necrosis factor-α (TNF-α). In vivo histopathological assessment showed that AzP reduced cisplatin-induced injury to the jejunum villi and triggered weight loss in the C57BL/6 mice. Immunohistochemistry (IHC) results demonstrated that mice treated with AzP also recovered from cisplatin-induced injury to the intestinal mucosa. Mechanistic in vitro study using DAVID/KEGG enrichment analysis of microarray data and confirmation by a Western blot indicated the influence of AzP on the MEK/ERK and AKT-dependent pathway. In conclusion, the study demonstrated that AzP might regulate the MEK/ERK MAPK signaling pathway to attenuate MCP-1, TNF-α, and IL-6 production and provide opportunities for the development of new anti-inflammatory drugs targeting mucositis.
原文英語
文章編號249
期刊International Journal of Molecular Sciences
20
發行號2
DOIs
出版狀態已發佈 - 一月 1 2019

指紋

monocytes
interleukins
Mucositis
Histone Deacetylase Inhibitors
Chemotherapy
necrosis
chemotherapy
inhibitors
mice
tumors
proteins
Proteins
Drug Therapy
Microarrays
viability
drugs
cancer
Cells
Chemokine CCL2
Mitogen-Activated Protein Kinase Kinases

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

引用此文

Efficacy of azatyrosine-phenylbutyric hydroxamides, a histone deacetylase inhibitor, on chemotherapy-induced gastrointestinal mucositis. / Liao, Po Lin; Huang, Shih Hsuan; Hung, Chien Hung; Huang, Wei Kuang; Tsai, Chi Hao; Kang, Jaw Jou; Wang, Hui Po; Cheng, Yu Wen.

於: International Journal of Molecular Sciences, 卷 20, 編號 2, 249, 01.01.2019.

研究成果: 雜誌貢獻文章

Liao, Po Lin ; Huang, Shih Hsuan ; Hung, Chien Hung ; Huang, Wei Kuang ; Tsai, Chi Hao ; Kang, Jaw Jou ; Wang, Hui Po ; Cheng, Yu Wen. / Efficacy of azatyrosine-phenylbutyric hydroxamides, a histone deacetylase inhibitor, on chemotherapy-induced gastrointestinal mucositis. 於: International Journal of Molecular Sciences. 2019 ; 卷 20, 編號 2.
@article{1fc1b3eca5f74b7e888c71edaa4af930,
title = "Efficacy of azatyrosine-phenylbutyric hydroxamides, a histone deacetylase inhibitor, on chemotherapy-induced gastrointestinal mucositis",
abstract = "Gastrointestinal mucositis is a serious side effect of chemotherapy. Currently, no effective treatment exists for chemotherapy-induced mucositis, prompting the need to develop an anti-mucositis agent for use in clinics. The present study investigated whether azatyrosine-PBHA (AzP), a histone deacetylase inhibitor, has a therapeutic effect on intestinal mucosa. The results indicated that AzP did not affect the proliferation and viability of cancer cells, outcomes that are achieved by suberoylanilide hydroxamic acid (SAHA). However, AzP could decrease production of the inflammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor-necrosis factor-α (TNF-α). In vivo histopathological assessment showed that AzP reduced cisplatin-induced injury to the jejunum villi and triggered weight loss in the C57BL/6 mice. Immunohistochemistry (IHC) results demonstrated that mice treated with AzP also recovered from cisplatin-induced injury to the intestinal mucosa. Mechanistic in vitro study using DAVID/KEGG enrichment analysis of microarray data and confirmation by a Western blot indicated the influence of AzP on the MEK/ERK and AKT-dependent pathway. In conclusion, the study demonstrated that AzP might regulate the MEK/ERK MAPK signaling pathway to attenuate MCP-1, TNF-α, and IL-6 production and provide opportunities for the development of new anti-inflammatory drugs targeting mucositis.",
keywords = "Anti-inflammation, Azatyrosine-phenylbutyric hydroxamides (PBHA), Histone deacetylase inhibitor (HDACi), Mucositis",
author = "Liao, {Po Lin} and Huang, {Shih Hsuan} and Hung, {Chien Hung} and Huang, {Wei Kuang} and Tsai, {Chi Hao} and Kang, {Jaw Jou} and Wang, {Hui Po} and Cheng, {Yu Wen}",
year = "2019",
month = "1",
day = "1",
doi = "10.3390/ijms20020249",
language = "English",
volume = "20",
journal = "International Journal of Molecular Sciences",
issn = "1661-6596",
publisher = "MDPI AG",
number = "2",

}

TY - JOUR

T1 - Efficacy of azatyrosine-phenylbutyric hydroxamides, a histone deacetylase inhibitor, on chemotherapy-induced gastrointestinal mucositis

AU - Liao, Po Lin

AU - Huang, Shih Hsuan

AU - Hung, Chien Hung

AU - Huang, Wei Kuang

AU - Tsai, Chi Hao

AU - Kang, Jaw Jou

AU - Wang, Hui Po

AU - Cheng, Yu Wen

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Gastrointestinal mucositis is a serious side effect of chemotherapy. Currently, no effective treatment exists for chemotherapy-induced mucositis, prompting the need to develop an anti-mucositis agent for use in clinics. The present study investigated whether azatyrosine-PBHA (AzP), a histone deacetylase inhibitor, has a therapeutic effect on intestinal mucosa. The results indicated that AzP did not affect the proliferation and viability of cancer cells, outcomes that are achieved by suberoylanilide hydroxamic acid (SAHA). However, AzP could decrease production of the inflammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor-necrosis factor-α (TNF-α). In vivo histopathological assessment showed that AzP reduced cisplatin-induced injury to the jejunum villi and triggered weight loss in the C57BL/6 mice. Immunohistochemistry (IHC) results demonstrated that mice treated with AzP also recovered from cisplatin-induced injury to the intestinal mucosa. Mechanistic in vitro study using DAVID/KEGG enrichment analysis of microarray data and confirmation by a Western blot indicated the influence of AzP on the MEK/ERK and AKT-dependent pathway. In conclusion, the study demonstrated that AzP might regulate the MEK/ERK MAPK signaling pathway to attenuate MCP-1, TNF-α, and IL-6 production and provide opportunities for the development of new anti-inflammatory drugs targeting mucositis.

AB - Gastrointestinal mucositis is a serious side effect of chemotherapy. Currently, no effective treatment exists for chemotherapy-induced mucositis, prompting the need to develop an anti-mucositis agent for use in clinics. The present study investigated whether azatyrosine-PBHA (AzP), a histone deacetylase inhibitor, has a therapeutic effect on intestinal mucosa. The results indicated that AzP did not affect the proliferation and viability of cancer cells, outcomes that are achieved by suberoylanilide hydroxamic acid (SAHA). However, AzP could decrease production of the inflammatory mediators interleukin-6 (IL-6), monocyte chemoattractant protein-1 (MCP-1), and tumor-necrosis factor-α (TNF-α). In vivo histopathological assessment showed that AzP reduced cisplatin-induced injury to the jejunum villi and triggered weight loss in the C57BL/6 mice. Immunohistochemistry (IHC) results demonstrated that mice treated with AzP also recovered from cisplatin-induced injury to the intestinal mucosa. Mechanistic in vitro study using DAVID/KEGG enrichment analysis of microarray data and confirmation by a Western blot indicated the influence of AzP on the MEK/ERK and AKT-dependent pathway. In conclusion, the study demonstrated that AzP might regulate the MEK/ERK MAPK signaling pathway to attenuate MCP-1, TNF-α, and IL-6 production and provide opportunities for the development of new anti-inflammatory drugs targeting mucositis.

KW - Anti-inflammation

KW - Azatyrosine-phenylbutyric hydroxamides (PBHA)

KW - Histone deacetylase inhibitor (HDACi)

KW - Mucositis

UR - http://www.scopus.com/inward/record.url?scp=85059896047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059896047&partnerID=8YFLogxK

U2 - 10.3390/ijms20020249

DO - 10.3390/ijms20020249

M3 - Article

C2 - 30634582

AN - SCOPUS:85059896047

VL - 20

JO - International Journal of Molecular Sciences

JF - International Journal of Molecular Sciences

SN - 1661-6596

IS - 2

M1 - 249

ER -